Your browser doesn't support javascript.
loading
Cosyntropin testing does not predict response to glucocorticoids in community-acquired pneumonia in a randomized controlled trial.
Blum, Claudine A; Schuetz, Philipp; Nigro, Nicole; Winzeler, Bettina; Arici, Birsen; Refardt, Julie; Urwyler, Sandrine A; Rodondi, Nicolas; Blum, Manuel R; Briel, Matthias; Mueller, Beat; Christ-Crain, Mirjam.
Afiliação
  • Blum CA; Endocrinology, Diabetology and Metabolism, Department of Internal Medicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.
  • Schuetz P; Department of General Internal & Emergency Medicine and Department of Endocrinology, Diabetology and Clinical Nutrition, Medical University Clinic, Kantonsspital Aarau, Aarau, Switzerland.
  • Nigro N; Department of General Internal & Emergency Medicine and Department of Endocrinology, Diabetology and Clinical Nutrition, Medical University Clinic, Kantonsspital Aarau, Aarau, Switzerland.
  • Winzeler B; Endocrinology, Diabetology and Metabolism, Department of Internal Medicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.
  • Arici B; Endocrinology, Diabetology and Metabolism, Department of Internal Medicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.
  • Refardt J; Endocrinology, Diabetology and Metabolism, Department of Internal Medicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.
  • Urwyler SA; Endocrinology, Diabetology and Metabolism, Department of Internal Medicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.
  • Rodondi N; Endocrinology, Diabetology and Metabolism, Department of Internal Medicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.
  • Blum MR; Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
  • Briel M; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Mueller B; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Christ-Crain M; Department of Clinical Research, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel and University of Basel, Basel, Switzerland.
Clin Endocrinol (Oxf) ; 91(3): 374-382, 2019 09.
Article em En | MEDLINE | ID: mdl-30485501
ABSTRACT

OBJECTIVE:

Glucocorticoids have been shown to improve outcome in community-acquired pneumonia (CAP). However, glucocorticoids have potential side-effects, and treatment response may vary. It is thus crucial to select patients with high likelihood to respond favourably. In critical illness, cosyntropin testing is recommended to identify patients in need for glucocorticoids. We investigated whether cosyntropin testing predicts treatment response to glucocorticoids in CAP.

DESIGN:

Predefined secondary analysis of a randomized controlled trial. PATIENTS Hospitalized patients with CAP. MEASUREMENTS We performed 1 µg cosyntropin tests in a randomized trial comparing prednisone 50 mg for 7 days to placebo. We investigated whether subgroups based on baseline and stimulated cortisol levels responded differently to glucocorticoids with regard to time to clinical stability (TTCS) and other outcomes by inclusion of interaction terms into statistical models.

RESULTS:

A total of 326 patients in the prednisone and 309 patients in the placebo group were evaluated. Neither basal cortisol nor a Δcortisol <250 nmol/L after stimulation nor the combination of basal cortisol and Δcortisol predicted treatment response as measured by TTCS (all P for interaction >0.05). Similarly, we found no effect modification with respect to mortality, rehospitalization, antibiotic treatment duration or CAP-related complications (all P for interaction >0.05). However, glucocorticoids had a stronger effect on shortening length of hospital stay in patients with a baseline cortisol of ≥938 nmol/L (P for interaction = 0.015).

CONCLUSIONS:

Neither baseline nor stimulated cortisol after low-dose cosyntropin testing at a dose of 1 µg predicted glucocorticoid responsiveness in mild to moderate CAP. A treatment decision for or against adjunct glucocorticoids in CAP should not be made depending on cortisol values or cosyntropin testing results.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia / Cosintropina / Valor Preditivo dos Testes / Glucocorticoides Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Endocrinol (Oxf) Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia / Cosintropina / Valor Preditivo dos Testes / Glucocorticoides Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Endocrinol (Oxf) Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Suíça